こんにちは由美子です

Similar documents
こんにちは由美子です

分布

こんにちは由美子です

Phase II clinical trials for patients with cancer

80 X 1, X 2,, X n ( λ ) λ P(X = x) = f (x; λ) = λx e λ, x = 0, 1, 2, x! l(λ) = n f (x i ; λ) = i=1 i=1 n λ x i e λ i=1 x i! = λ n i=1 x i e nλ n i=1 x

% 10%, 35%( 1029 ) p (a) 1 p 95% (b) 1 Std. Err. (c) p 40% 5% (d) p 1: STATA (1). prtesti One-sample test of pr

AR(1) y t = φy t 1 + ɛ t, ɛ t N(0, σ 2 ) 1. Mean of y t given y t 1, y t 2, E(y t y t 1, y t 2, ) = φy t 1 2. Variance of y t given y t 1, y t

untitled

日本統計学会誌, 第44巻, 第2号, 251頁-270頁

Rによる計量分析:データ解析と可視化 - 第3回 Rの基礎とデータ操作・管理

Visual Evaluation of Polka-dot Patterns Yoojin LEE and Nobuko NARUSE * Granduate School of Bunka Women's University, and * Faculty of Fashion Science,

1 Stata SEM LightStone 3 2 SEM. 2., 2,. Alan C. Acock, Discovering Structural Equation Modeling Using Stata, Revised Edition, Stata Press.

tnbp59-21_Web:P2/ky132379509610002944

Stata 11 Stata ROC whitepaper mwp anova/oneway 3 mwp-042 kwallis Kruskal Wallis 28 mwp-045 ranksum/median / 31 mwp-047 roctab/roccomp ROC 34 mwp-050 s

JMP V4 による生存時間分析

研修コーナー

パーキンソン病治療ガイドライン2002

Microsoft Word - StatsDirectMA Web ver. 2.0.doc

untitled

ECCS. ECCS,. ( 2. Mac Do-file Editor. Mac Do-file Editor Windows Do-file Editor Top Do-file e

10

28

I L01( Wed) : Time-stamp: Wed 07:38 JST hig e, ( ) L01 I(2017) 1 / 19

カテゴリ変数と独立性の検定

1 Stata SEM LightStone 4 SEM 4.. Alan C. Acock, Discovering Structural Equation Modeling Using Stata, Revised Edition, Stata Press 3.

症例数設定? What is sample size estimation? 医療機器臨床試験のコンサルティングで最も相談件数が多いのは 症例数の設定 Many a need of consulting for device clinical trial is sample size estimat

α β *2 α α β β α = α 1 β = 1 β 2.2 α 0 β *3 2.3 * *2 *3 *4 (µ A ) (µ P ) (µ A > µ P ) 10 (µ A = µ P + 10) 15 (µ A = µ P +

Studies of Foot Form for Footwear Design (Part 9) : Characteristics of the Foot Form of Young and Elder Women Based on their Sizes of Ball Joint Girth

(pdf) (cdf) Matlab χ ( ) F t

y i OLS [0, 1] OLS x i = (1, x 1,i,, x k,i ) β = (β 0, β 1,, β k ) G ( x i β) 1 G i 1 π i π i P {y i = 1 x i } = G (

Vol. 36, Special Issue, S 3 S 18 (2015) PK Phase I Introduction to Pharmacokinetic Analysis Focus on Phase I Study 1 2 Kazuro Ikawa 1 and Jun Tanaka 2

第90回日本感染症学会学術講演会抄録(I)

2007-Kanai-paper.dvi

第11回:線形回帰モデルのOLS推定

Ł\”ƒ-2005

64 3 g=9.85 m/s 2 g=9.791 m/s 2 36, km ( ) 1 () 2 () m/s : : a) b) kg/m kg/m k

untitled

自由集会時系列part2web.key


yamadaiR(cEFA).pdf

kiyo5_1-masuzawa.indd

positron 1930 Dirac 1933 Anderson m 22Na(hl=2.6years), 58Co(hl=71days), 64Cu(hl=12hour) 68Ge(hl=288days) MeV : thermalization m psec 100

2016.

第121回関東連合産科婦人科学会総会・学術集会 プログラム・抄録

本文/目次(裏白)

スライド 1

kubostat2018d p.2 :? bod size x and fertilization f change seed number? : a statistical model for this example? i response variable seed number : { i

臨床試験

Microsoft Word - 計量研修テキスト_第5版).doc

¥¤¥ó¥¿¡¼¥Í¥Ã¥È·×¬¤È¥Ç¡¼¥¿²òÀÏ Âè2²ó

こんにちは由美子です

鉄鋼協会プレゼン

tokei01.dvi

2 ( ) i

Stata11 whitepapers mwp-037 regress - regress regress. regress mpg weight foreign Source SS df MS Number of obs = 74 F(

k2 ( :35 ) ( k2) (GLM) web web 1 :

k3 ( :07 ) 2 (A) k = 1 (B) k = 7 y x x 1 (k2)?? x y (A) GLM (k

²¾ÁÛ¾õ¶·É¾²ÁË¡¤Î¤¿¤á¤Î¥Ñ¥Ã¥±¡¼¥¸DCchoice ¡Ê»ÃÄêÈÇ¡Ë

層化

ICU ( ) ICU ( ) ICU SpO 2 ICU ( ) -297 S.E DEX: N=30 DEX: N= 6 (J-DEX Placebo: N=30 Placebo: N= 3 65 DEX: N=16 DEX: N= 3 Placebo: N=


nsg04-28/ky208684356100043077

udc-2.dvi

日本製薬工業協会シンポジウム 生存時間解析の評価指標に関する最近の展開ー RMST (restricted mean survival time) を理解するー 2. RMST の定義と統計的推測 2018 年 6 月 13 日医薬品評価委員会データサイエンス部会タスクフォース 4 生存時間解析チー

, (GPS: Global Positioning Systemg),.,, (LBS: Local Based Services).. GPS,.,. RFID LAN,.,.,.,,,.,..,.,.,,, i

bosai-2002.dvi

10:30 12:00 P.G. vs vs vs 2

Microsoft Word - 計量研修テキスト_第5版).doc


II (No.2) 2 4,.. (1) (cm) (2) (cm) , (

塗装深み感の要因解析

早稲田大学現代政治経済研究所 ダブルトラック オークションの実験研究 宇都伸之早稲田大学上條良夫高知工科大学船木由喜彦早稲田大学 No.J1401 Working Paper Series Institute for Research in Contemporary Political and Ec

y = x 4 y = x 8 3 y = x 4 y = x 3. 4 f(x) = x y = f(x) 4 x =,, 3, 4, 5 5 f(x) f() = f() = 3 f(3) = 3 4 f(4) = 4 *3 S S = f() + f() + f(3) + f(4) () *4

漸化式のすべてのパターンを解説しましたー高校数学の達人・河見賢司のサイト


news


untitled

¼§À�ÍýÏÀ – Ê×ÎòÅŻҼ§À�¤È¥¹¥Ô¥ó¤æ¤é¤® - No.7, No.8, No.9

Vol. 29, No. 2, (2008) FDR Introduction of FDR and Comparisons of Multiple Testing Procedures that Control It Shin-ichi Matsuda Department of

2.2 h h l L h L = l cot h (1) (1) L l L l l = L tan h (2) (2) L l 2 l 3 h 2.3 a h a h (a, h)

オーストラリア研究紀要 36号(P)☆/3.橋本

数理統計学Iノート


Stata User Group Meeting in Kyoto / ( / ) Stata User Group Meeting in Kyoto / 21

講義のーと : データ解析のための統計モデリング. 第2回

Microsoft Word - Power_Analysis_Jp_ docx

A Study of Adaptive Array Implimentation for mobile comunication in cellular system GD133

J. Jpn. Soc. Soil Phys. No. 126, p (2014) ECH 2 O 1 2 Calibration of the capacitance type of ECH 2 O soil moisture sensors Shoichi MITSUISHI 1 a

日本内科学会雑誌第97巻第7号

2 2 1?? 2 1 1, 2 1, 2 1, 2, 3,... 1, 2 1, 3? , 2 2, 3? k, l m, n k, l m, n kn > ml...? 2 m, n n m

A Nutritional Study of Anemia in Pregnancy Hematologic Characteristics in Pregnancy (Part 1) Keizo Shiraki, Fumiko Hisaoka Department of Nutrition, Sc

N cos s s cos ψ e e e e 3 3 e e 3 e 3 e


2 1 1 α = a + bi(a, b R) α (conjugate) α = a bi α (absolute value) α = a 2 + b 2 α (norm) N(α) = a 2 + b 2 = αα = α 2 α (spure) (trace) 1 1. a R aα =

σ t σ t σt nikkei HP nikkei4csv H R nikkei4<-readcsv("h:=y=ynikkei4csv",header=t) (1) nikkei header=t nikkei4csv 4 4 nikkei nikkei4<-dataframe(n

.. est table TwoSLS1 TwoSLS2 GMM het,b(%9.5f) se Variable TwoSLS1 TwoSLS2 GMM_het hi_empunion totchr

ADM-Hamiltonian Cheeger-Gromov 3. Penrose

日本内科学会雑誌第98巻第4号

2 The Bulletin of Meiji University of Integrative Medicine 3, Yamashita 10 11

Transcription:

Sample size power calculation Sample Size Estimation AZTPIAIDS AIDSAZT AIDSPI AIDSRNA AZTPr (S A ) = π A, PIPr (S B ) = π B AIDS (sampling)(inference) π A, π B π A - π B = 0.20 PI 20 20AZT, PI 10 6 8 HIV-RNA 20 n A = AZT S A = AZTn B = PI S B = PI π A = S A /n A, π B = S B /n B, AIDS =δ = π A - π B 1

H 0 : = 0 H A : 0 δh 0 reject H A accept δ π π π π δ Sample α/2 = 0.025 α/2 = 0.025 You Sample H 0 God Truth H A H 0 A=B (OK) Type II error (β error) H A Type I error A is not B (α error) truth A B A B Type I error(α error) A B Type II error(β error)fda α error β error 2

Truth Sample β -error Power = 1 - β -error power? If difference of means increase, If sample number increased β-error one side 2 AIDS AZT 20PI 30 HIV-RNA α = 0.05 (two sided), β = 0.20 ( power = 80%) α = 0.05 (two sided) δ = (0.3 0.2)/0.3 (1 0.3) + 0.2 (1 0.2) = 0.1644 n =[(Zα + Zβ)/d] 2 = [(1.96 + 0.84)/0.1644] 2 = 290 AZT 290 PI 290 580 3

Power 90two sided test α = 0.05, 35% 4550 60 10 35% 45% (0.45 0.35) / (0.45 x 0.55 + 0.35 x 0.65) = 0.145 [(1.96 + 1.28) / 0.145] = 500 / 50% 60% (0.60 0.50) / (0.60 x 0.50 + 0.50 x 0.50) = 0.143 [(1.96 + 1.28) / 0.143] = 513 / 4

α 5

6

7

success / failure AIDSAZT 24 HIV-RNA µ A PIµ B H 0 : µ A - µ B =0 H A :µ A - µ B 0 AIDS X A, X B µ A - µ B X A - X B X A - X B sample variance (Zα + Zβ) 2 δ 2 δ = µ 1 µ 2 8

SD (Zα + Zβ) 2 δ 2 δ = µ 1 µ 2 24 2 SD 20 10 6 [ 2 x S 2 (Zα + Zβ) 2 / 2 ] = [2 x 20 2 x (1.96 + 0.84) 2 ]/10 2 = 63/arm [ 2 x S 2 (Zα + Zβ) 2 / 2 ] = [2 x 20 2 x (1.96 + 0.84) 2 ]/6 2 = 175/arm 95(confidence interval) 95(confidence interval) 100 4 300 SE 950 1200 350 900 100 4 95 95 950 1000 200 3000 Sample size 95CI (π B π A ) π π π π standard error (SE) phase II trial (1 arm) 95CI 95 10 10 9

100 95 10 one arm ππ When π = 0.8, n = 62 When π = 0.7, n = 81 When π = 0.6, n = 93 When π = 0.5, n = 96 When π = 0.4, n = 93 When π = 0.3, n = 81 When π = 0.2, n = 62 When π = 0.1, n = 35 50 Clinical Equivalence Trials Bio-equivalence under the curve Cmax Clinical Equivalence Trials 10 Clinical Equivalence Trials one side AZT AIDS ddi AIDS D 10 0.1 < D < 0.1 ddi AZT AZT OK (standard) 0.7 (new) 0.5 10

= πs πn 95% CI upper 0.2 95%CI 0.2 OK 95% CI upper 95CI 0.2 (πs πn)+ 1.65[πS (1 - πs)/n + πs (1 - πs)/n] πs = πn=0.7 sample size 1.65[πS (1 - πs)/n + πs (1 - πs)/n] = 0.2 1.65[2 x 0.7(1 0.7)/n]=0.2 n = 29 / arm 0.6 πs πn=0.1 1.65[πS (1 - πs)/n + πs (1 - πs)/n] = 0.1 1.65[2 x 0.7(1 0.7)/n]=0.1 n = 115 / arm sample size 11

(πs πn)+ 1.65[πS (1 - πs)/n + πs (1 - πs)/n]=(0.80 0.75) + 1.65[0.80 (1 0.80)/100 + 0.75 (1 0.75)/100] = 0.147 10% 0.147 p 1 p 2 95CI 10simple mastectomynon-equivalent α β δ δ α β δ 100 200 equivalent 12

Hazard function Prob (T>t) = e λt H 0 : λ 1(t) = λ 2(t) H A : λ 1(t) = constant λ 2(t) 2 *hazard rate λ 1 /λ 2 * = ln(λ 1 /λ 2 )/2 d =[(Zα + Zβ)/*] 2 d: X 1 (λ 1 ) 1 1 1.5 (λ 2 )α = 0.05, power = 80% * = ln(λ 1 /λ 2 )/2 = ln(1.5)/2 = 0.287 d = [(1.96 + 0.84) / 0.287] 2 = 96 96 96 Years of additional follow-up 1 2 3 Years 1 150 117 104 of 2 132 110 103 accrual 3 122 107 102 Accrual follow-up accrual 1 follow-up 2 3 Prob (T>t) = e λt 1 1 13

t = 11 Prob (T>1) = e λ1 = 0.5 ln (0.5) = - 0.69 λ 1 = 0.69 λ 1 /λ 2 = 1.5 = 0.69/λ 2 λ 2 = 0.46 Hazard function λ Accrual years = A, Follow-up years = F F A/2 A/2 + F accrual 2 2 2/2 + 2 = 3 3 3 Prob (T>t) = e λt 3 T failure time Prob (T>3) = e λt = e 0.69 x 3 = 0.126 3 1 - Prob (T<3) = 1-0.126 = 0.873 Prob (T>3) = e λt = e 0.46 x 3 = 0.252 3 1 - Prob (T<3) = 1-0.252 = 0.748 96 sample size event 3 87.3 74.8 96 96 87.3%, 74.8% 14

(sample size) 110 128 238 accrual AIDS 1.5 2 randomized clinical trial AIDS AIDS 300 150 3 (accrual)1 Type I error 5%, type II error 20% Prob (T>t) = e λt H 0 : λ 1(t) = λ 2(t) H A : λ 1(t) = constant λ 2(t) * = ln(λ 1 /λ 2 )/2 = ln(2.0/1.5)/2 = 0.203 d = [(1.96 + 0.84) / 0.203] 2 = 190.24 190 190 Prob (T>t) = e λt 1.5 Prob (T>1.5) = e λ x 1.5 = 0.5 ln (0.5) = - 0.46 λ 1 = 0.46 λ 1 /λ 2 = 2.0/1.5 = 1.33= 0.46/λ 2 λ 2 = 0.35 15

accrual 3 1 3/2 + 1 = 2.5 2.5 2.5 Prob (T>t) = e λt 2.5 T failure time Prob (T>2.5) = e λt = e 0.46 x 2.5 = 0.317 2.5 1 - Prob (T<2.5) = 1-0.317 = 0.683 Prob (T>2.5) = e λt = e 0.35 x 2.5 = 0.417 2.5 1 - Prob (T<2.5) = 1-0.417 = 0.583 96 sample size event 3 68.3 58.3 190 96 68.3%, 58.3% (sample size) 278 326 604 16

STATA sample size randomized placebo controlled clinical trial randomization 4 68 pilot study placebo 498 ± 20.2 sec, 485 ± 19.5 sec 0.7 change method α = 0.05 (two sided), 90% power STATA command. sampsi 498 485, sd1(20.2) sd2(19.5) method(change) pre(1) post(3) r1(.7) Estimated sample size for two samples with repeated measures Assumptions: alpha = 0.0500 (two-sided) power = 0.9000 m1 = 498 m2 = 485 sd1 = 20.2 sd2 = 19.5 n2/n1 = 1.00 number of follow-up measurements = 3 correlation between follow-up measurements = 0.700 number of baseline measurements = 1 correlation between baseline & follow-up = 0.700 Method: CHANGE relative efficiency = 2.500 adjustment to sd = 0.632 adjusted sd1 = 12.776 adjusted sd2 = 12.333 Estimated required sample sizes: n1 = 20 n2 = 20 placebo 20 17

Clinical trials with repeated measures 30 15. sampsi 498 485, sd1(20.2) sd2(19.5) method(change) pre(1) post(3) r1(.7) n1(1 5) n2(15) Estimated power for two samples with repeated measures Assumptions: alpha = 0.0500 (two-sided) m1 = 498 m2 = 485 sd1 = 20.2 sd2 = 19.5 sample size n1 = 15 n2 = 15 n2/n1 = 1.00 number of follow-up measurements = 3 correlation between follow-up measurements = 0.700 number of baseline measurements = 1 correlation between baseline & follow-up = 0.700 Method: CHANGE relative efficiency = 2.500 adjustment to sd = 0.632 adjusted sd1 = 12.776 adjusted sd2 = 12.333 Estimated power: power = 0.809. 80 30 placebo 20. sampsi 498 485, sd1(20.2) sd2(19.5) method(change) pre(1) post(3) r1(.7) n1(20) n2(15) Estimated power for two samples with repeated measures Assumptions: alpha = 0.0500 (two-sided) m1 = 498 m2 = 485 sd1 = 20.2 sd2 = 19.5 sample size n1 = 20 n2 = 15 18

n2/n1 = 0.75 number of follow-up measurements = 3 correlation between follow-up measurements = 0.700 number of baseline measurements = 1 correlation between baseline & follow-up = 0.700 Method: CHANGE relative efficiency = 2.500 adjustment to sd = 0.632 adjusted sd1 = 12.776 adjusted sd2 = 12.333. Estimated power: power = 0.860 86 19

Two-sample test of equality of proportions Yes/no type 10 3 10 3 sample size H 0 reject α = 0.05, power 0.80 sample. sampsi 0.1 0.03, power(0.8) Estimated sample size for two-sample comparison of proportions Test Ho: p1 = p2, where p1 is the proportion in population 1 and p2 is the proportion in population 2 Assumptions: alpha = 0.0500 (two-sided) power = 0.8000 p1 = 0.1000 p2 = 0.0300 n2/n1 = 1.00 Estimated required sample sizes: n1 = 222 n2 = 222 1 222 phase I trial 90. sampsi 0.1 0.03, power(0.9) Estimated sample size for two-sample comparison of proportions Test Ho: p1 = p2, where p1 is the proportion in population 1 and p2 is the proportion in population 2 Assumptions: alpha = 0.0500 (two-sided) power = 0.9000 p1 = 0.1000 p2 = 0.0300 n2/n1 = 1.00 Estimated required sample sizes: n1 = 287 n2 = 287 287 20

300 placebo 150. sampsi 0.1 0.03, n1(300) r(0.5) Estimated power for two-sample comparison of proportions Test Ho: p1 = p2, where p1 is the proportion in population 1 and p2 is the proportion in population 2 Assumptions: alpha = 0.0500 (two-sided) p1 = 0.1000 p2 = 0.0300 sample size n1 = 300 n2 = 150 n2/n1 = 0.50 Estimated power: power = 0.7185. placebo 2:1 80. sampsi 0.1 0.03, power(0.8) r(0.5) Estimated sample size for two-sample comparison of proportions Test Ho: p1 = p2, where p1 is the proportion in population 1 and p2 is the proportion in population 2 Assumptions: alpha = 0.0500 (two-sided) power = 0.8000 p1 = 0.1000 p2 = 0.0300 n2/n1 = 0.50 Estimated required sample sizes: n1 = 349 n2 = 175 21

One sample test of proportion 8 6 50 golden standard 75 a = 0.05, 80. sampsi 0.5 0.75, power(0.8) onesample Estimated sample size for one-sample comparison of proportion to hypothesized value Test Ho: p = 0.5000, where p is the proportion in the population Assumptions: alpha = 0.0500 (two-sided) power = 0.8000 alternative p = 0.7500 Estimated required sample size: n = 29 29 historical comparison randomized clinical trial. sampsi 0.5 0.75, power(0.8) onesample Estimated sample size for one-sample comparison of proportion to hypothesized value Test Ho: p = 0.5000, where p is the proportion in the population Assumptions: alpha = 0.0500 (two-sided) power = 0.8000 alternative p = 0.7500 Estimated required sample size: n = 29 22

Two sample test of equality of means endpoint 105 mmhg SD 10 mmhg 98 SD 10 placebo 2:1 80α = 0.05. sampsi 105 98, p(0.8) r(2) sd1(10) sd2(10) Estimated sample size for two-sample comparison of means Test Ho: m1 = m2, where m1 is the mean in population 1 and m2 is the mean in population 2 Assumptions: alpha = 0.0500 (two-sided) power = 0.8000 m1 = 105 m2 = 98 sd1 = 10 sd2 = 10 n2/n1 = 2.00 Estimated required sample sizes: n1 = 25 n2 = 50 23